1. Home
  2. Clinical Topics
  3. FDA approves treatment for hepatitis C in children
Clinical TopicsDrugs and DevicesWeb Exclusives

FDA approves treatment for hepatitis C in children

Share

On April 30, the FDA approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17.

Read more at fda.gov.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts